Ipsen
Open enrollment across a mixed-phase pipeline
According to ClinicalTrials.gov-derived indexes, Ipsen sits in the top decile of US sponsors by registered trial count (#268 of 15,742 sponsors by registered trial count).
Ipsen: 85 sponsored US clinical trials, 16 recruiting.
Ipsen sponsors 85 registered US clinical trials on ClinicalTrials.gov, 16 of them currently recruiting, and 50 completed. 33 of these trials are in Phase 3-4 (later-stage) and 28 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Primary Biliary Cholangitis, with 3 trials.
Top-decile sponsor footprint
Ipsen ranks in the top decile of sponsors by registered trial count (#268 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
50 of 62 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (80.6%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
85 total, page 1 of 2
A Study to Assess How Well and Safely Elafibranor Works in Adult Participants With Primary Sclerosing Cholangitis
NCT07387549
A Study to Assess the Effectiveness and Safety of IPN10200 in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
NCT07427797
A Study to Assess the Effectiveness and Safety of IPN10200 Over Time in Adults With Moderate to Severe Wrinkle-like Lines Between the Eyebrows
NCT07435428
A Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, Immunogenicity and Anti-tumour Activity of IPN01203 in Adults With Locally Advanced or Metastatic Solid Tumours Exposed to Immune Checkpoint Inhibitor Therapies
NCT07213830
A Study to Assess the Safety, Tolerability, Pharmacokinetic, Pharmacodynamic, Immunogenicity and Antitumour Activity of IPN60300 in Adults With Locally Advanced or Metastatic Solid Tumours
NCT07213817
A Study of IPN10200 for the Treatment of Cervical Dystonia in Adults
NCT06937931
A Study Observing the Long-term, Effectiveness and Safety of Odevixibat (Bylvay) in Patients With Alagille Syndrome (ALGS) Who Are Receiving Ongoing Treatment
NCT06850038
A Study to Assess a New Medicine Called IPN01195 When Administered Alone in Adults With Advanced Solid Tumours
NCT06833008
A Study to Document and to Further Describe Long-term Safety and Effectiveness of Palovarotene in Participants With Fibrodysplasia Ossificans Progressiva (FOP)
NCT06089616
A Study Observing Everyday Effectiveness and Safety of the Drug Elafibranor in Participants With Primary Biliary Cholangitis Who Are Receiving Ongoing Treatment
NCT06447168
A Study to Evaluate IPN10200 Safety and Efficacy in the Prevention of Episodic or Chronic Migraine in Adults
NCT06625060
A Study to Assess IPN01194 When Administered Alone in Adults With Advanced Solid Tumours
NCT06305247
A Study to Estimate How Often Post-stroke Spasticity Occurs and to Provide a Standard Guideline on the Best Way to Monitor Its Development
NCT06055725
Odevixibat Pregnancy and Lactation Surveillance Program: A Study to Evaluate the Safety of Odevixibat During Pregnancy and/or Lactation
NCT06258902
A Long-Term Study of Elafibranor in Adult Participants With Primary Biliary Cholangitis
NCT06016842
A Study to Assess the Safety and Efficacy of IPN10200 in Adult Participants With Upper Limb Spasticity.
NCT04752774
A Study Describing Scratch and Sleep Patterns in Patients With Primary Biliary Cholangitis (Luminaria)
NCT07049887
Effects of Maintenance Cabozantinib+BSC Versus BSC in Children and AYA With Osteosarcoma
NCT06341712
A Study of Elafibranor in Adults With Primary Biliary Cholangitis and Inadequate Response or Intolerance to Ursodeoxycholic Acid.
NCT06383403
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Chronic Migraine in Adults
NCT06047444
A Study to Evaluate the Effectiveness and Safety of Dysport® for the Prevention of Episodic Migraine in Adults
NCT06047457
A Study to Assess Safety and Effectiveness of Elafibranor in Adult Participants With Primary Sclerosing Cholangitis.
NCT05627362
Study of Elafibranor in Patients With Primary Biliary Cholangitis (PBC)
NCT04526665
A Study of the Blood Levels of Palovarotene in Participants With Abnormal Liver Function Compared to Healthy Adult Participants After Intake of a Single Dose
NCT06908954
A Study to Understand Participant's Experiences in Gastro-enteropancreatic Neuroendocrine Tumors (GEP-NETs) and Acromegaly
NCT06253897
A Study to Collect Participants Experience of Living With Adult Upper Limb (AUL) Spasticity and to Assess the Arm Activity Measure (ArmA)
NCT05546190
Study to Compare the Level of Elafibranor in Blood After Repeat Administration in Japanese and Non-Asian Healthy Participants
NCT05543369
A Rollover Study to Further Evaluate the Safety and Efficacy of Palovarotene Capsules in Male and Female Participants Aged ≥14 Years With Fibrodysplasia Ossificans Progressiva (FOP) Who Have Completed the Relevant Parent Studies.
NCT05027802
A Study to Compare the Safety and Efficacy of Dysport® and Botox® in Adults With Upper Limb Spasticity.
NCT04936542
An International Cross-sectional Survey to Evaluate the Burden of Fibrodysplasia Ossificans Progressiva (FOP) on Patients and Their Families.
NCT04665323
A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment
NCT04083235
Study Of Cabozantinib Treatment In Patients With Unresectable, Locally Advanced Or Metastatic Renal Cell Carcinoma Who Progressed After Previous Treatment With Checkpoint Inhibitors
NCT04353765
Study to Assess the Effectiveness of AboBoNT-A Injections for Adult Lower Limb Spasticity in a Real Life Cohort
NCT04050527
Evaluate the Safety, Tolerability, Biodistribution and Anti Tumour Activity of 177LU-OPS201 With Companion Imaging 68Ga-OPS202 PET/CT in Previously Treated Subjects With Locally Advanced or Metastatic Cancers Expressing Somatostatin Receptor 2 (SSTR2)
NCT03773133
Dose Escalation and Dose Expansion Study of IPN60090 in Patients With Advanced Solid Tumours
NCT03894540
Validation of Patient Reported Outcome Measures for Use in Vulvodynia
NCT03770169
Validation of Patient Reported Outcome Measures for Use in Hallux Valgus
NCT03846687
Dysport in Hallux Abducto Valgus (HAV) Phase IIa
NCT03569098
Dysport in Vulvodynia Phase II Study
NCT03598777
Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.
NCT03525392
Study of Irinotecan Liposome Injection (ONIVYDE®) in Patients With Small Cell Lung Cancer
NCT03088813
To Evaluate the Optimal Dose of 68Ga-OPS202 as a PET (Positron Emission Tomography) Imaging Agent in Subjects With Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)
NCT03220217
Lanreotide and Octreotide Long Acting Release (LAR) for Patients With Advanced Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)
NCT03017690
Switching From Octreotide to Lanreotide - A Look Back at Patients With Neuroendocrine Tumors
NCT03112694
Efficacy and Safety of Lanreotide Autogel/ Depot 120 mg vs. Placebo in Subjects With Lung Neuroendocrine Tumours
NCT02683941
Study to Evaluate the Safety and Preliminary Efficacy of 177Lu-OPS201 in NETs
NCT02592707
Effectiveness and Safety of Dysport® (abobotulinumtoxinA) in Paediatric Lower Limb Spasticity
NCT03017729
Study to Evaluate Effects of DYSPORT® Injected in Lower and Upper Limb Combined With Guided Self-Rehabilitation Contract (GSC)
NCT02969356
Dysport® Treatment of Urinary Incontinence in Adults Subjects With Neurogenic Detrusor Overactivity (NDO) Due to Spinal Cord Injury or Multiple Sclerosis - Study 1
NCT02660138
Community-based Neuroendocrine Tumor (NET) Research Study
NCT02730104
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 13 |
| Phase 2 | 15 |
| Phase 3 | 30 |
| Phase 4 | 3 |
Therapeutic Areas
What is open in the Ipsen pipeline
16 recruiting of 85 indexed (19% open); 50 completed (59%).
Phase mix: 33 late (III/IV) vs 28 early (I/II) (balanced across stages).
Top condition: Primary Biliary Cholangitis (3 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Ipsen: open-pipeline peers nationwide
Peers matched on 85 registered trials and 19% open enrollment, not the therapeutic-area sidebar.
Ipsen sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 85 trials (± recruiting share)
- Intermountain Health Care · 85 trials · 13% recruiting
- Seagen · 84 trials · 0% recruiting
- Ferring Pharmaceuticals · 83 trials · 5% recruiting
- National Jewish Health · 83 trials · 8% recruiting
Sponsors near 19% open enrollment (± trial volume)
- Spaulding Rehabilitation Hospital · 19% recruiting · 101 trials
- Medical University of South Carolina · 19% recruiting · 755 trials
- EyePoint Pharmaceuticals · 19% recruiting · 16 trials
- Hebrew SeniorLife · 19% recruiting · 32 trials
Related
What to do with this Ipsen page
85 registered trials is a research-attention snapshot, not an endorsement of Ipsen or any single study.
- 16 of Ipsen's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Primary Biliary Cholangitis is the condition Ipsen studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Primary Biliary Cholangitis trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Ipsen pipeline card: 85 registered trials from official public datasets.Report a data error.